Haemtech Biopharma Services

Characterization of IXINITY®, recombinant factor IX from Emergent BioSolutions, Inc.

Here is an article in Advanced Hematology (February 2016) illustrating some of our work characterizing recombinant FIX from Emergent BioSolutions, Inc. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779506/

Haemtech Biopharma Services Validates First Thrombin Generation Assay for Commercial IVIG Product Release


Haemtech Biopharma Services (HBS) is pleased to announce the successful validation of a thrombin generation assay (TGA) for an IVIG drug. The assay was validated in 2012 to support the use of TGA as a release assay for Biotest Pharmaceuticals

Read more ›